Opposite to HDAC1/HDAC2, overexpression of HDAC3 in breast cancer is associated with clinicopathological indicator of disease progression [34], which is in line with our result , HDAC3 increased of expression after treatment with TSA in MCF-7. This evidence concerns the gene HDAC1 and breast carcinoma.